Session Type: Poster Session (Sunday)
Session Time: 9:00AM-11:00AM
Background/Purpose: Axial spondyloarthritis (AxSpa) is characterized by inflammation in the sacroiliac joints and spine and associated with extracellular matrix (ECM) remodelling of affected tissues. Type VI collagen (COL6) is an ECM protein located in the interface between the basement membrane and interstitial matrix, where is binds to other ECM proteins and support cell-cell interactions. C6M is a metabolite of COL6 that is released from the inflamed tissue and can be measured in serum as a biomarker of tissue remodelling. The aim of this study was to investigate the association of C6M in patients with AxSpA, and its relationship with treatment of TNF-α inhibitors for 46 weeks in the prospective Biomarkers in Spondyloarthritis (BIOSPA) study.
Methods: C6M was measured in serum from the BIOSPA study (n=55) at baseline, week 2, 22, 46 after treatment with TNF-inhibitors (infliximab, etanercept or adalimumab). Differences between the biomarker levels at the four different timepoints were calculated using repeated measures ANOVA. A t-test was used to calculate the improvement is ASDAS, while Spearman correlations were performed to explore the association of C6M and MRI measures.
Results: Patients included were 82% males, with median age of 40 years (IQR: 32-48), and 84% were human leucocyte antigen-B27 positive. They had a median disease duration of 5.5 years (IQR: 2-10), and a median baseline level of ASDAS 3.9 (IQR: 3.0-4.5). The levels of C6M can be found in Table 1. Levels of C6M were significantly decreased after 2 and 22 weeks of treatment compared to baseline (p=0.0014 and p=0.0015, respectively). C6M was significantly decreased in patients with clinical important improvement after 22 weeks (ASDAS ≥Δ1.1) (p=0.010) and major improvement after 22 and 46 weeks (ASDAS ≥Δ2.0) (p=0.0002 and p=0.018, respectively) as shown in Table 2 and 3. Baseline and week 22 levels of C6M correlated to the total SPARCC Spine and Sacroiliac Joint Inflammation score measured by MRI (Spearmans Rho=0.496, p< 0.001 and Spearmans Rho=0.297, p=0.031 respectively).
Conclusion: The biomarker C6M was associated with changes in ASDAS and MRI measures of inflammation during TNF-inhibitor treatment. This indicates that C6M may be a tissue-based marker of disease activity.
To cite this abstract in AMA style:Holm Nielsen S, Bay-Jensen A, Østergaard M, Siebuhr A, Karsdal M, Sørensen i, Weber U, Loft A, Kollerup G, Thamsborg G, Rintek Madsen O, Møller J, Juhl Pedersen S. A Biomarker of Type VI Collagen Degradation (C6M) Is Associated with Changes in ASDAS MRI Measures of Inflammation in Patients with Axial Spondyloarthritis During TNF Inhibitor Therapy [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/a-biomarker-of-type-vi-collagen-degradation-c6m-is-associated-with-changes-in-asdas-mri-measures-of-inflammation-in-patients-with-axial-spondyloarthritis-during-tnf-inhibitor-therapy/. Accessed July 8, 2020.
« Back to 2019 ACR/ARP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-biomarker-of-type-vi-collagen-degradation-c6m-is-associated-with-changes-in-asdas-mri-measures-of-inflammation-in-patients-with-axial-spondyloarthritis-during-tnf-inhibitor-therapy/